Stockscreener 앱 받기
100.98
0.31%
-0.31
시간 외 거래:
100.90
-0.08
-0.08%
전일 마감가:
$101.29
열려 있는:
$101.08
하루 거래량:
6.72M
Relative Volume:
0.68
시가총액:
$174.73B
수익:
$46.59B
순이익/손실:
$5.41B
주가수익비율:
32.64
EPS:
3.0938
순현금흐름:
$7.38B
1주 성능:
-1.94%
1개월 성능:
-10.22%
6개월 성능:
-2.89%
1년 성능:
-24.39%
1일 변동 폭
$100.25
$101.76
1주일 범위
$100.09
$104.54
52주 변동 폭
$81.97
$135.45
애보트 래버러토리스 Stock (ABT) Company Profile
명칭
Abbott Laboratories
전화
(224) 667-6100
주소
100 ABBOTT PARK ROAD, ABBOTT PARK, IL
Compare ABT vs MDT, SYK, BSX, EW
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ABT
Abbott Laboratories
|
100.98 | 175.27B | 46.59B | 5.41B | 7.38B | 3.0938 |
MDT
Medtronic Plc
|
89.50 | 113.38B | 36.36B | 4.84B | 5.43B | 3.7261 |
SYK
Stryker Corp
|
275.31 | 104.47B | 25.27B | 3.34B | 4.57B | 8.6334 |
BSX
Boston Scientific Corp
|
44.11 | 63.65B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
86.83 | 49.74B | 6.30B | 1.07B | 1.09B | 1.8406 |
애보트 래버러토리스 Stock (ABT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-04-22 | 다운그레이드 | Daiwa Securities | Outperform → Neutral |
| 2025-10-10 | 개시 | The Benchmark Company | Buy |
| 2025-07-18 | 업그레이드 | Jefferies | Hold → Buy |
| 2025-06-16 | 개시 | Leerink Partners | Market Perform |
| 2024-10-08 | 개시 | Oppenheimer | Outperform |
| 2024-09-19 | 개시 | Piper Sandler | Overweight |
| 2024-07-30 | 다운그레이드 | Edward Jones | Buy → Hold |
| 2024-05-30 | 개시 | Goldman | Buy |
| 2023-07-21 | 업그레이드 | Wolfe Research | Underperform → Peer Perform |
| 2023-05-30 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2023-04-20 | 재확인 | Barclays | Overweight |
| 2023-04-20 | 재확인 | Bernstein | Outperform |
| 2023-04-20 | 재확인 | JP Morgan | Overweight |
| 2023-04-20 | 재확인 | Raymond James | Outperform |
| 2023-04-20 | 재확인 | UBS | Buy |
| 2023-04-20 | 재확인 | Wolfe Research | Underperform |
| 2023-03-29 | 개시 | UBS | Buy |
| 2022-10-26 | 개시 | Mizuho | Neutral |
| 2022-10-18 | 개시 | Barclays | Overweight |
| 2022-10-12 | 개시 | Jefferies | Hold |
| 2022-07-06 | 개시 | Wolfe Research | Underperform |
| 2022-03-02 | 재개 | BofA Securities | Buy |
| 2022-01-27 | 재확인 | Credit Suisse | Outperform |
| 2022-01-27 | 재확인 | Morgan Stanley | Overweight |
| 2022-01-27 | 재확인 | Raymond James | Outperform |
| 2022-01-27 | 재확인 | UBS | Buy |
| 2021-12-10 | 개시 | RBC Capital Mkts | Outperform |
| 2021-10-27 | 업그레이드 | Atlantic Equities | Neutral → Overweight |
| 2021-10-14 | 개시 | Redburn | Neutral |
| 2021-05-25 | 개시 | Barclays | Overweight |
| 2021-04-15 | 개시 | Atlantic Equities | Neutral |
| 2021-01-28 | 업그레이드 | BTIG Research | Neutral → Buy |
| 2020-09-11 | 개시 | Wolfe Research | Outperform |
| 2020-06-01 | 다운그레이드 | Goldman | Neutral → Sell |
| 2020-03-05 | 개시 | Citigroup | Buy |
| 2020-02-13 | 개시 | Goldman | Neutral |
| 2020-02-06 | 재개 | BTIG Research | Neutral |
| 2020-01-02 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2019-06-13 | 재확인 | BofA/Merrill | Buy |
| 2019-02-07 | 재확인 | BofA/Merrill | Buy |
| 2019-01-02 | 다운그레이드 | Citigroup | Neutral → Sell |
| 2018-11-30 | 업그레이드 | Goldman | Neutral → Buy |
| 2018-10-16 | 개시 | Barclays | Overweight |
| 2018-06-27 | 개시 | Bernstein | Outperform |
| 2018-01-30 | 재확인 | Citigroup | Neutral |
| 2018-01-25 | 재확인 | Stifel | Buy |
| 2018-01-25 | 업그레이드 | William Blair | Mkt Perform → Outperform |
| 2018-01-03 | 개시 | Evercore ISI | Outperform |
| 2018-01-02 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2018-01-02 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2017-10-19 | 재확인 | RBC Capital Mkts | Outperform |
| 2017-10-19 | 재확인 | Stifel | Buy |
모두보기
애보트 래버러토리스 주식(ABT)의 최신 뉴스
Gilead vs. Abbott: Which Dividend Healthcare Stock Offers the Better Risk-Reward? - Yahoo Finance
3 Dividend Stocks To Watch As High Rates Test Defensive Shares - simplywall.st
Form 4 Abbott Laboratories For: 25 September By Investing.com - Investing.com India
At $103.99 a share, an Abbott Laboratories (ABT) director delivered or withheld shares for exercise costs or taxes. - Stock Titan
Abbott Laboratories stock falls 2.32 percent below yearly high effects? no - AD HOC NEWS
Is Abbott Laboratories (NYSE:ABT) Facing a Real Market Test? - Kalkine Media
Abbott Laboratories stock loses 1.82 percent before the bell - ad-hoc-news.de
How Lingo Partnership Will Impact Abbott Stock (ABT) - simplywall.st
Abbott to pay nearly $385 million to settle infant formula allegations - ConsumerAffairs
Abbott Laboratories (ABT) is Facing Segment Competition and Sluggish Nutrition Recovery - Yahoo Finance
Abbott Laboratories stock reports Q2 growth and earnings beat - AD HOC NEWS
Mexico Cardiac Rhythm Management Devices Market Outlook to 2036 Provides Revenue, Volume, Pricing and Competitive Insig - GlobeNewswire Inc.
Abbott Laboratories stock rises 0.69 percent ahead of the open - AD HOC NEWS
Abbott partners with Berry Street to add nutrition coaching to Lingo - Drug Delivery Business
Abbott Laboratories stock ends the day 0.69 percent higher at USD 103.69 - AD HOC NEWS
Abbott Laboratories: A Strong Business At A Fair Price (NYSE:ABT) - Seeking Alpha
Sinocare Asks Court To Rule Device Won't Infringe Abbott IP - Law360
What Makes Abbott Laboratories (ABT) an Attractive Opportunity? - Yahoo Finance
Abbott and Berry Street team up on personalized nutrition tracking - marketscreener.com
Is Abbott Laboratories (ABT) Still Undervalued On Volt’s First US And Canada Procedures? - simplywall.st
Abbott Laboratories (ABT) Is a Trending Stock: Facts to Know Before Betting on It - Yahoo Finance
Abbott and Berry Street partner to combine gluc... - Pluang
A 15% discount on Abbott's four-week glucose-monitor plans will go to Berry Street users. - Stock Titan
Abbott Laboratories stock gains 1.12 percent as settlement weighs - AD HOC NEWS
US companies face rise in cyber attacks - Reuters
Abbott Laboratories stock heads into the open after a 1.12 percent gain - AD HOC NEWS
The Premium On Abbott Laboratories Keeps Growing. So Does The Case For Stryker and Boston Scientific - Trefis
Calls to sign infant formula testing bill into law in New York - Spectrum News
Abbott Laboratories stock ends the day 1.12 percent higher - AD HOC NEWS
Abbott to pay almost $385M in DOJ settlement over infant formula plant allegations - Compliance Week
Abbott: Quality Remains, But Exact Sciences Has Raised The Bar For Buy (NYSE:ABT) - Seeking Alpha
Sibionics Challenges Abbott Patent In Glucose Monitor Fight - Law360
3 Health Care Stocks With Whale Alerts In Today’s Session - benzinga.com
Abbott Laboratories stock gains 0.36 percent as revenue reaches USD 12.6 billion - AD HOC NEWS
Abbott Laboratories stock heads into the open after a 0.7 percent gain - AD HOC NEWS
Abbott vs. Intuitive Surgical: Two Healthcare Titans on Diverging Growth Curves - NAI500
Abbott Laboratories Agencies, 2018 - OpenSecrets
NC gets $216K from Abbott baby formula settlement - WSOC TV
NC reaches settlement with Abbott over contaminated baby formula that led to 2022 shortage - WRAL
Abbott Laboratories stock ends the day modestly higher at the close - AD HOC NEWS
Abbott Laboratories Lobbyists, 2022 - OpenSecrets
Abbott Laboratories Agencies, 2012 - OpenSecrets
Abbott Laboratories vs. Intuitive Surgical: Recent Quarterly Revenue Trends Reveal a Classic Investing Truth - The Motley Fool
Abbott Laboratories To Pay $385M Over Allegations Of Tainted Infant Formula - Patch
Abbott Laboratories Agencies, 2002 - OpenSecrets
Abbott Laboratories stock slips 2.0 percent after Friday close - AD HOC NEWS
Abbott Laboratories Agrees to Pay Over $384 Million to Settle Allegations Related to Contaminated Infant Formula - Sierra Sun Times
Abbott Laboratories stock heads into the open after a 2.0 percent drop. - AD HOC NEWS
Wheels Up for Oslo, With One New Slide: Abbott Paid $385 Million, and Nobody Was Charged - Marler Blog
Abbott Laboratories stock holds near USD 102 after July results - AD HOC NEWS
Why Is the Market Reassessing Abbott Laboratories (ABT)? - Kalkine Media
애보트 래버러토리스 (ABT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.97%
자본화:
|
볼륨(24시간):